Jeff Yass’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $211K | Buy |
89,000
+27,200
| +44% | +$70.3K | ﹤0.01% | 11827 |
|
|
2026
Q2 | $167K | Buy |
61,800
+11,300
| +22% | +$20.9K | ﹤0.01% | 12116 |
|
|
2026
Q1 | $60.6K | Buy |
+50,500
| New | +$61.5K | ﹤0.01% | 12578 |
|
|
2025
Q3 | – | Sell |
-98,300
| Closed | -$110K | – | 12790 |
|
|
2025
Q2 | $110K | Buy |
+98,300
| New | +$114K | ﹤0.01% | 11732 |
|
|
2025
Q1 | – | Sell |
-25,500
| Closed | -$42.1K | – | 12744 |
|
|
2024
Q4 | $42.1K | Buy |
+25,500
| New | +$64.3K | ﹤0.01% | 11747 |
|
|
2024
Q3 | – | Sell |
-11,900
| Closed | -$39K | – | 12258 |
|
|
2024
Q2 | $39K | Sell |
11,900
-49,200
| -81% | -$215K | ﹤0.01% | 11501 |
|
|
2024
Q1 | $448K | Buy |
+61,100
| New | +$378K | ﹤0.01% | 8772 |
|
|
2023
Q1 | – | Sell |
-28,000
| Closed | -$283K | – | 12813 |
|
|
2022
Q4 | $283K | Buy |
28,000
+7,100
| +34% | +$133K | ﹤0.01% | 9240 |
|
|
2022
Q3 | $468K | Buy |
20,900
+6,200
| +42% | +$179K | ﹤0.01% | 8673 |
|
|
2022
Q2 | $364K | Sell |
14,700
-35,700
| -71% | -$985K | ﹤0.01% | 9030 |
|
|
2022
Q1 | $1.95M | Buy |
50,400
+21,200
| +73% | +$821K | ﹤0.01% | 5532 |
|
|
2021
Q4 | $1.71M | Sell |
29,200
-11,800
| -29% | -$669K | ﹤0.01% | 5890 |
|
|
2021
Q3 | $2.43M | Sell |
41,000
-29,000
| -41% | -$2.27M | ﹤0.01% | 5416 |
|
|
2021
Q2 | $6.08M | Sell |
70,000
-42,400
| -38% | -$3.42M | ﹤0.01% | 3668 |
|
|
2021
Q1 | $9.27M | Buy |
112,400
+61,300
| +120% | +$5.87M | ﹤0.01% | 2890 |
|
|
2020
Q4 | $4.65M | Buy |
51,100
+4,400
| +9% | +$273K | ﹤0.01% | 3522 |
|
|
2020
Q3 | $1.87M | Sell |
46,700
-26,000
| -36% | -$908K | ﹤0.01% | 4755 |
|
|
2020
Q2 | $2.49M | Sell |
72,700
-40,400
| -36% | -$1.2M | ﹤0.01% | 4104 |
|
|
2020
Q1 | $2.51M | Sell |
113,100
-47,800
| -30% | -$1.21M | ﹤0.01% | 3570 |
|
|
2019
Q4 | $3.15M | Sell |
160,900
-16,800
| -9% | -$267K | ﹤0.01% | 3631 |
|
|
2019
Q3 | $2.76M | Sell |
177,700
-97,600
| -35% | -$1.87M | ﹤0.01% | 3629 |
|
|
2019
Q2 | $5.59M | Buy |
275,300
+76,300
| +38% | +$1.37M | ﹤0.01% | 2570 |
|
|
2019
Q1 | $3.5M | Buy |
199,000
+54,600
| +38% | +$862K | ﹤0.01% | 2924 |
|
|
2018
Q4 | $1.85M | Buy |
144,400
+46,400
| +47% | +$647K | ﹤0.01% | 3635 |
|
|
2018
Q3 | $1.6M | Buy |
98,000
+61,600
| +169% | +$728K | ﹤0.01% | 4363 |
|
|
2018
Q2 | $413K | Sell |
36,400
-9,900
| -21% | -$109K | ﹤0.01% | 7187 |
|
|
2018
Q1 | $452K | Buy |
+46,300
| New | +$444K | ﹤0.01% | 6839 |
|
Other funds holding FATE
Jeff Yass's FATE Position: Q3 2026 in Review
Jeff Yass increased its Fate Therapeutics (FATE) stake by 206% in Q3 2026, buying an estimated $2.72M and bringing the position to 1,563,709 shares worth $3.71M. The position accounts for ﹤0.01% of the portfolio, ranked #5010.
Jeff Yass first reported a position in FATE in Q4 2017 and has held it in 33 quarters since. The position peaked at $6.44M in Q4 2020. 142 funds tracked by Wall St. Rank hold FATE as of Q3 2026.
- Jeff Yass held 1,563,709 shares of Fate Therapeutics worth $3.71M as of Q3 2026.
- Jeff Yass bought 1,052,659 Fate Therapeutics shares in Q3 2026, an estimated $2.72M.
- Fate Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #5010 holding.
- Jeff Yass first reported a position in Fate Therapeutics in Q4 2017 and has held it in 33 quarters since.
- Jeff Yass's Fate Therapeutics position peaked at $6.44M in Q4 2020.
- 142 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.
Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.